



**TALIGEN ANNOUNCES THAT TT30, A NOVEL PROTEIN TARGETING THE COMPLEMENT SYSTEM, WILL BE HIGHLIGHTED IN TWO PRESENTATIONS AT THE AMERICAN SOCIETY OF HEMATOLOGY MEETING**

Cambridge, MA, November 10, 2009 – Taligen Therapeutics, a biotechnology company at the forefront of developing therapies that regulate the complement system to treat inflammatory and immune diseases, announced today that preclinical data for TT30, its lead drug candidate, will be presented at the 51<sup>st</sup> Annual Meeting of the American Society of Hematology in New Orleans, LA on December 5-8, 2009.

TT30 is a novel fusion protein comprised of naturally-occurring protein structures that selectively binds to complement activated cells and locally regulates the complement system. TT30 is being developed as a potential treatment of inflammatory and autoimmune diseases, and some immune-related renal and hematology diseases. TT30 was created using Taligen’s novel inflammatory tissue targeting platform to enable local and targeted regulation of the undesirable effects of excessive amplification of the complement system.

The schedule is as follows:

- **Abstract #3021, Poster Board #II-997: Sunday, December 6, 2009, 6:00 – 8:00 p.m.,** “TT30, a Novel Human Protein Therapeutic, Selectively Modulates the Complement Alternative Pathway by Targeted Supplementation of Local Factor H Activity”, Holers, et al. Ernest N. Morial Convention Center, Hall E.
- **Abstract #158, Oral Session - Red Cell Erythropoiesis Structure and Function, Metabolism, and Survival (Excluding Iron): Erythropoiesis and PNH: Sunday, December 6, 2009, 4:45pm,** “TT30, A Novel Regulator of the Complement Alternative Pathway (CAP), Inhibits Hemolysis of Paroxysmal Nocturnal Hemoglobinuria (PNH) Erythrocytes and Prevents Upstream C3 Binding On Their Surface in An In Vitro Model”, Risitano, et al. Ernest N. Morial Convention Center, 220-222.

**About Taligen Therapeutics**

Taligen Therapeutics is a biotechnology company pioneering a new approach to treating inflammatory and immune diseases by regulating the complement system, a potent and ubiquitous immune pathway. Based on new insights and unique proprietary technology related to complement biology, Taligen is building a deep product candidate pipeline of novel protein therapeutics which selectively identify,

target and concentrate on inflammatory tissues. Taligen's targeted drugs have been shown to naturally and broadly control aberrant inflammation in a broad array of genetic, orphan and large market diseases. Founded in 2004, Taligen Therapeutics maintains its headquarters in Cambridge, Massachusetts. For additional information about the Company, please visit [www.taligetherapeutics.com](http://www.taligetherapeutics.com).

**Contact:**

Gina Nugent

Yates Public Relations

Tel: 617-460-3579

###